| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President, R& D
1 company
Andrew Stewart Plump is President, R& D at TKPHF. Andrew Stewart Plump's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $6.1M at current prices.
The TKPHF filings lean toward selling, a net 301,235 shares.
Andrew Stewart Plump has 5 Form 4 filings on record from April 2026 to September 2026, all as President, R & D at Takeda Pharmaceutical (TKPHF), 2026.
The 5 reported transactions were 3 open-market sales and 2 stock awards.
Counted by filing, the open-market trades come to no purchases and 3 sales worth about $5.3M.
The largest open-market sale was 165,393 shares of TKPHF at an average $17.10 on August 10, 2026, about $2.8M.
2 of the 3 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other was not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | TKPHF Takeda Pharmaceutical Company Limited | President, R& D | Sell10b5-1 | 116,191 | $18.49 | $2,148,371.59 | -44.4% | |
| Aug 19, 2026 | TKPHF Takeda Pharmaceutical Company Limited | President, R& D | Sell10b5-1 | 19,651 | $18.49 | $363,346.99 | -7.0% | |
| Aug 10, 2026 | TKPHF Takeda Pharmaceutical Company Limited | President, R& D | Sell | 165,393 | $17.10 | $2,828,220.30 | -17.7% |